Back To TOP

What We Offer

Pulmozyme Access Solutions offers services to help you navigate the access and reimbursement process. Click on the icons to visit the following sections of our website.







Pulmozyme Access Solutions Specialists can help you with benefits and coverage issues such as benefits investigations and prior authorization.





Pulmozyme Access Solutions Specialists can help you by guiding you through denials and appeals and providing billing and coding information.




Patient Assistance

Patient assistance offerings through Pulmozyme Access Solutions can help your patients obtain the therapy prescribed, regardless of their ability to pay.




Product Distribution

Get information on product distribution methods.*




My Patient Solutions

Manage patient access with this online patient management resource.



Communication Assistance Services

As part of our commitment to your patients, we offer language translation and hearing-impaired services to anyone calling Pulmozyme Access Solutions. This way, we can ensure individual communication needs are not a barrier to accessing our patient and practice support services. Our interpretation services are available for a variety of languages. In addition, telephone-to-telephone typewriter (TTY) services are available for hearing-impaired callers.



Learn More About
  • LEARN about treatment with Pulmozyme
  • FIND the right patient assistance program with our Compass for Patient Access tool
  • LEARN HOW the Pulmozyme Co-pay Card Program can help with the out-of-pocket costs for Pulmozyme
  • Download: new forms for enrollment in GATCF
  • Form Statement of Medical Necessity
  • Form Patient Authorization and Notice of Release of Information (Current Version)

Pulmozyme Indication and Important Safety Information


Daily administration of Pulmozyme Inhalation Solution in conjunction with standard therapies is indicated in the management of cystic fibrosis (CF) patients to improve pulmonary function. In patients with an FVC ≥40% of predicted, daily administration of Pulmozyme has also been shown to reduce the risk of respiratory tract infections requiring parenteral antibiotics. Safety and efficacy of daily administration have not been demonstrated in patients for longer than 12 months.


  • Pulmozyme is contraindicated in patients with known hypersensitivity to dornase alfa, Chinese hamster ovary cell products, or any component of the product
  • Pulmozyme should be used in conjunction with standard therapies for CF
  • Most common reported adverse events associated with the use of Pulmozyme include: voice alteration, pharyngitis, laryngitis, rash, chest pain, and conjunctivitis

You may report side effects to the FDA at (800) FDA-1088 or You may also report side effects to Genentech at (888) 835-2555.

Please see full prescribing information for Pulmozyme, including additional Important Safety Information.